SCTB41 Plus Docetaxel for Advanced Lung Cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of two drugs—SCTB41 (a new immunotherapy) and docetaxel (a chemotherapy)—in patients with advanced non-small cell lung cancer who have already tried other treatments. The goal is to see if this combination can slow or stop cancer growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced lung cancer (Stage IIIB, IIIC, or IV) that cannot be surgically removed or treated with radiation and chemotherapy together
- Your cancer has grown or returned after treatment with immunotherapy (PD-1/PD-L1 inhibitors) and/or chemotherapy
- You have not previously received the drug docetaxel
- You have good overall health and can perform light activity (ECOG score 0–1)
- You have at least one tumor that can be measured on imaging and is not in the brain
- Your major organs (liver, kidneys, heart, lungs) are working well enough for treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug (SCTB41) combined with chemotherapy for people with advanced squamous non-small cell lung cancer who have not had any prior treatment. It aims to see if this combination works better than standard therapy.
This trial tests a new drug, SCTB14, as a first treatment for advanced non-small cell lung cancer that has a high level of PD-L1. It aims to see if the drug is safe and effective for people who haven't had other treatments for their cancer.
This trial tests a new experimental drug called PF-08046054/SGN-PDL1V against a standard chemotherapy (docetaxel) for people with a type of advanced lung cancer that has PD-L1 protein on at least 1% of tumor cells and has progressed after prior treatments. The goal is to see if the new drug works better or has fewer side effects.
This Phase 3 trial compares AL2846 pills plus TQB2450 injections against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer. You may qualify if your cancer has progressed after platinum chemotherapy and immunotherapy, and if certain tumor genetic tests are negative.
This trial tests a new drug called SCTB41 in people with advanced solid tumors that have not responded to other treatments. The goal is to see if it is safe and if it shrinks tumors.
This trial tests whether a new drug combination (SYS6010 plus enlonstobart) works better than standard immunotherapy with chemotherapy for patients with advanced non-small cell lung cancer. You may qualify if you have not received prior cancer treatment and have a specific marker (PD-L1) on your tumor.
Hear when a new NSCLC (Advanced Non-small Cell Lung Cancer) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.